Nyxoah Enhances Production Capacity in Belgium
The Belgian medical device specialist for the treatment of obstructive sleep apnea announces an investment in expanding its manufacturing capabilities in Wallonia. This decision comes in a context of increasing demand in the United States and international markets, according to the group.
Expansion of Production Facilities
Nyxoah has signed an agreement with LégiaPark, a life sciences business park located in the Liège region, the press release states. The project includes the creation of a nearly 2,000 square meter production unit, which will feature a cleanroom developed in collaboration with ABN Cleanroom Technology. This new infrastructure complements the company's existing contract manufacturing activities in the United States. The facility will also incorporate spaces dedicated to product development and storage. According to ABN Cleanroom Technology, the cleanroom has been designed to be scalable and can be expanded in the short term to meet Nyxoah's future production needs. The chosen Configure-to-Order Plus approach integrates the essential values of a cleanroom from the design stage while offering operational flexibility from day one.
Strategic Investment and Market Expansion
Olivier Taelman, CEO of Nyxoah, explains this investment by a strong commercial momentum in the United States and a rapidly expanding international demand. The stated goal is to increase production capacity and strengthen the group's gross margin, according to his statements. Nyxoah develops and markets the Genio system, a probeless and battery-free hypoglossal nerve neurostimulation therapy designed to treat obstructive sleep apnea. The device received CE marking in 2019 and FDA approval in August 2025 for a subgroup of adult patients with moderate to severe obstructive sleep apnea. The company has been listed on Euronext Brussels since September 2020 and on the Nasdaq since July 2021.
Strengthening Strategic Partnerships and Local Job Creation
This agreement strengthens the strategic partnership with Noshaq and is expected to contribute to local job creation, the press release indicates. Isabelle Degand, CEO of LégiaPark, emphasizes that these specialized and custom-designed technical spaces illustrate the strength of the Belgian life sciences ecosystem. The project reflects the long-standing relationship between Nyxoah and the Belgian ecosystem. LégiaPark, located on the heights of Liège opposite the CHC Mont-Légia, is a 30,000 square meter business center dedicated to companies active in life sciences and advanced technologies. The infrastructure offers laboratories and cleanrooms as well as a range of shared services, and aims to become a reference hub in Wallonia for innovation in the medical technology and biopharmacy sectors.
